Healthcare & Pharmaceuticals

Antibody levels predictive of Moderna's vaccine efficacy -study

2 minute read

A healthcare worker holds a vial of the Moderna COVID-19 Vaccine at a pop-up vaccination site operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in Manhattan in New York City, New York, U.S., January 29, 2021. REUTERS/Mike Segar

Register now for FREE unlimited access to reuters.com

NEW YORK, Aug 10 (Reuters) - Antibody levels are a good predictor for how effective Moderna Inc's (MRNA.O) COVID-19 vaccine is, according to a new study released on Tuesday, a finding which could help speed up future clinical trials for vaccines against the disease.

Regulators currently rely on large placebo-controlled studies to determine if a vaccine works, but the study, conducted by scientists from the Fred Hutchinson Cancer Research Center, the National Institute of Allergy and Infectious Diseases, Moderna and elsewhere, showed that measuring the antibody levels in vaccine recipients could also determine effectiveness.

The study, which has not yet been peer-reviewed, found that the Moderna vaccine was more effective in vaccine recipients with high levels of antibodies. These recipients also reported a lower rate of breakthrough infections after being vaccinated.

Register now for FREE unlimited access to reuters.com

The study was conducted using data from Moderna's 30,000-participant clinical trial, which started last year and was the basis for the vaccine's authorization.

Finding a surrogate measure of efficacy should speed regulators' decisions on vaccine approval even without large placebo-controlled studies, which could be impracticable to carry out if vaccines become widely available, said Peter Gilbert, a researcher at Fred Hutchinson and an author of the study.

Combined with data about the Pfizer (PFE.N)/BioNTech and AstraZeneca (AZN.L) vaccines, Gilbert said there has been a "consistent accumulation of evidence" showing that antibodies can be used as an alternate marker for vaccine efficacy.

Register now for FREE unlimited access to reuters.com
Reporting by Michael Erman; Editing by Karishma Singh

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters